30P OSE279, a PD-1-blocking Monoclonal Antibody, As Future Backbone of a Bifunctional Checkpoint Inhibitor Platform: Preliminary Results of a First-in-human (FIH) Study in Subjects with Advanced Malignancies

Anti-PD-1 antibodies have shown significant clinical efficacy with manageable safety. OSE279 is a humanized S228P- IgG4 monoclonal bivalent antibody against PD-1 which will be further used as the anti-PD-1 backbone component of a bifunctional checkpoint inhibitor BiCKI ® platform.